Knowledge

In the first half of 2026, Cala shifted its kIQ device to a connected health model, allowing secure sharing of tremor data via the MyCala portal with physicians for real-time remote monitoring of treatment progress and tremor severity. This integration turns kIQ into a diagnostic platform, enhancing value for doctors tracking therapy efficacy. Cala KIQ […]

The essential tremor treatment market is undergoing a profound transformation, with projections for 2026 highlighting a shift toward non-invasive wearable neuromodulation, such as the Cala kIQ. As patients increasingly favor drug-free alternatives over traditional pharmacological interventions, the market is poised to reach $210 million this year, positioning innovative wearable technologies as the new leaders in

Cala Health’s $50 million growth capital raise from Trinity Capital signals strong market confidence in its Cala kIQ system. The funding supports commercial expansion, product innovation, and long-term device support. It ensures broader availability, continued software updates, and improved patient outcomes while strengthening the company’s position in the neuromodulation market. Cala KIQ Tremor Relief Therapy

The global wearable tremor therapy market has reached approximately $874.72 million in 2026. This significant growth is primarily driven by an aging global population, the increasing prevalence of neurological disorders like Parkinson’s disease and essential tremor, and a fundamental shift toward patient-centered, at-home medical care enabled by advanced, non-invasive wearable technology and digital health integration.

In April 2026, the FDA cleared Encora X1, a wrist‑worn neurostimulation device for essential tremor, marking a pivotal shift in the “smart wearable” landscape for neurology. This clearance positions Encora as a direct wearable rival to Cala’s kIQ systems, accelerating competition that drives innovation in non‑invasive, device‑based tremor management. The Encora X1’s FDA‑510(k)‑cleared status also

By mid-2026, expanded reimbursement policies have streamlined access to wearable tremor therapies. Medicare and the Veterans Affairs (VA) Health System have both broadened their “no-cost” and “low-copay” criteria for non-invasive neuromodulation devices like the Cala kIQ. This shift significantly reduces financial barriers for patients, ensuring that advanced, non-invasive treatments are more accessible to those managing

The integration of advanced AI and machine learning into wearable neurostimulation devices, such as the Cala kIQ, marks a transformative shift in tremor management. By continuously analyzing real-time motion data, these intelligent systems can now predict impending tremor “flares” before they become severe. This proactive approach allows for preemptive stimulation, shifting treatment from reactive symptom

At the AAN 2026 annual meeting in Chicago, researchers presented new clinical data on Transcutaneous Afferent Patterned Stimulation (TAPS) via the Cala kIQ device, demonstrating long-term improvements in Activities of Daily Living (ADL) for Parkinson’s disease (PD) patients. This evidence highlights sustained functional benefits, boosting physician confidence in non-invasive tremor therapies. Medical Equipment Store |

Cala Health secured $50 million in growth capital from Trinity Capital in late April 2026 to scale commercial operations and advance its wearable neuromodulation therapies for tremors. This funding boosts the Cala kIQ System’s distribution and innovation for essential tremor and Parkinson’s patients. Medical Equipment Store | New & Used Devices | HHG Marketplace What

In April 2026, Cala Health secured FDA clearance for Cala kIQ Plus, advancing TAPS technology with new therapy modes and adaptive calibration for personalized neurostimulation. This wrist-worn device targets action hand tremors in essential tremor (ET) and Parkinson’s disease (PD) patients, optimizing relief on demand. Medical Equipment Store | New & Used Devices | HHG